NCT02758613View on ClinicalTrials.gov

A Study of Baricitinib (LY3009104) in Healthy Chinese Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

July 31, 2016

Study Completion Date

July 31, 2016

Conditions
Healthy
Interventions
DRUG

Baricitinib

Administered orally.

DRUG

Placebo

Administered orally.

Trial Locations (1)

100034

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Beijing

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT02758613 - A Study of Baricitinib (LY3009104) in Healthy Chinese Participants | Biotech Hunter | Biotech Hunter